Clean Air for Rare MUcociliary Clearance dIsorders (NCT07417267) | Clinical Trial Compass
By InvitationNot Applicable
Clean Air for Rare MUcociliary Clearance dIsorders
Cyprus62 participantsStarted 2025-05-01
Plain-language summary
The goal of this clinical trial is to learn whether using a high efficiency particulate air (HEPA) air purifier can improve respiratory health in children and adults with Cystic Fibrosis (CF) or Primary Ciliary Dyskinesia (PCD).
The main questions it aims to answer are:
Can using a HEPA air purifier at home reduce respiratory symptoms in people with CF or PCD?
Can it improve lung function and overall health?
Researchers will compare participants' health outcomes before and after the use of the HEPA air purifier to see if cleaner indoor air makes a measurable difference.
Participants will:
Visit the clinic for baseline health assessments (such as lung function and symptom questionnaires).
Have two HEPA air purifiers installed in their home. One device will be placed in the main living area and one in the bedroom.
Undergo exposure assessments during home visits to measure indoor air quality.
Who can participate
Age range
6 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age ≥6 years
* Physician-confirmed diagnosis of CF or PCD, based on internationally accepted criteria. PCD diagnosis will be based on either a) a positive genetic test (bi-allelic disease-causing mutations) or b) TEM class 1 defect, as defined by the European Respiratory Society and American Thoracic Society guidelines for the diagnosis of PCD. CF diagnosis will be based on the diagnostic criteria of the European Cystic Fibrosis Society Patient Registry including: (a) two sweat chloride test values of at least 60 mmol/L, or (b) one sweat chloride test value of at least 60 mmol/L and two disease-causing CFTR mutations, or (c) typical CF features at clinical presentation and two disease-causing CFTR mutations if sweat chloride test value was less than 60 mmol/L or not reported.
* Residing in a main household in Cyprus for at least 5 days per week during the study period.
* Willingness and ability to provide informed consent (or approval with guardian consent for minors).
Exclusion Criteria:
* Active smoking
* Hospitalization for any condition during the study period or lack of internet access, which is required for continuous data transmission
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
A mean difference of at least 10% change in the lung clearance index (LCI), measured at baseline, midpoint, and end of the study, between the two intervention groups.
Timeframe: From baseline to the end of the study at 6 months.